Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil EL&P Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Articles published by Neumora Therapeutics, Inc. Neumora Therapeutics to Host Key Opinion Leader Roundtable to Discuss the Potential of Navacaprant in Neuropsychiatric Disorders August 14, 2024 From Neumora Therapeutics, Inc. Via GlobeNewswire Tickers NMRA Neumora Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Update August 06, 2024 From Neumora Therapeutics, Inc. Via GlobeNewswire Tickers NMRA Neumora Therapeutics Announces Initiation of Phase 1b Study of NMRA-511 for Treatment of Alzheimer’s Disease Agitation June 20, 2024 From Neumora Therapeutics, Inc. Via GlobeNewswire Tickers NMRA Neumora Therapeutics Announces Initiation of Phase 2 Study of Navacaprant in Bipolar Depression May 14, 2024 From Neumora Therapeutics, Inc. Via GlobeNewswire Tickers NMRA Neumora Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update May 07, 2024 From Neumora Therapeutics, Inc. Via GlobeNewswire Tickers NMRA Neumora Therapeutics to Participate in Upcoming Conferences in May May 06, 2024 From Neumora Therapeutics, Inc. Via GlobeNewswire Tickers NMRA Neumora Therapeutics Announces Clinical Hold of Phase 1 NMRA-266 Study April 15, 2024 From Neumora Therapeutics, Inc. Via GlobeNewswire Tickers NMRA Neumora Therapeutics to Participate at Stifel 2024 Virtual CNS Days March 13, 2024 From Neumora Therapeutics, Inc. Via GlobeNewswire Tickers NMRA Neumora Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update March 07, 2024 From Neumora Therapeutics, Inc. Via GlobeNewswire Tickers NMRA Neumora Therapeutics Appoints Kaya Pai Panandiker as Chief Commercial Officer January 22, 2024 From Neumora Therapeutics, Inc. Via GlobeNewswire Tickers NMRA Neumora Therapeutics to Present at 42nd Annual J.P. Morgan Healthcare Conference January 02, 2024 From Neumora Therapeutics, Inc. Via GlobeNewswire Tickers NMRA Neumora Therapeutics Appoints Jason Duncan as Chief Legal Officer December 12, 2023 From Neumora Therapeutics, Inc. Via GlobeNewswire Tickers NMRA Neumora Therapeutics Announces NMRA-266 IND Clearance and Initiation of Phase 1 Clinical Study November 27, 2023 From Neumora Therapeutics, Inc. Via GlobeNewswire Tickers NMRA Neumora Therapeutics Reports Third Quarter 2023 Financial Results and Provides Business Update November 01, 2023 From Neumora Therapeutics, Inc. Via GlobeNewswire Tickers NMRA Neumora Therapeutics to Participate in Upcoming Conferences in November October 30, 2023 From Neumora Therapeutics, Inc. Via GlobeNewswire Tickers NMRA Neumora Therapeutics Announces Appointment of Robert Lenz, M.D., Ph.D., as Executive Vice President, Head of Research and Development October 10, 2023 From Neumora Therapeutics, Inc. Via GlobeNewswire Tickers NMRA Neumora Therapeutics Announces Pricing of Initial Public Offering September 14, 2023 From Neumora Therapeutics, Inc. Via GlobeNewswire Neumora Therapeutics Announces Initiation of Phase 3 Clinical Program for Navacaprant (NMRA-140) in Major Depressive Disorder July 18, 2023 From Neumora Therapeutics, Inc. Via Business Wire Neumora Therapeutics Names Henry Gosebruch as President and Chief Executive Officer July 18, 2023 From Neumora Therapeutics, Inc. Via Business Wire Neumora Therapeutics Announces $112 Million Series B Financing October 11, 2022 From Neumora Therapeutics, Inc. Via Business Wire Neumora Expands Precision Neuroscience Pipeline with Novel M4 Receptor Modulator Program Through Exclusive License Agreement with Vanderbilt University February 17, 2022 From Neumora Therapeutics, Inc. Via Business Wire Neumora Therapeutics Launches to Pioneer a New Era of Precision Medicines for Brain Diseases October 07, 2021 From Neumora Therapeutics, Inc. Via Business Wire Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.